ClinicalTrials.gg
Active, not recruitingNCT06953583BRAVEUpdated Oct 2, 2026

A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia

A Phase 3 interventional study of Omaveloxolone and Placebo in Friedreich Ataxia, sponsored by Biogen. Active, not recruiting at 34 sites in 16 countries. Open to participants aged 2 Years to 15 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Biogen · Phase 3, Interventional, and Treatment

Updated Oct 2, 2026Now Active, not recruitingGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
255
Allocation
Randomized
Ages
2 Years to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 71 studies in Friedreich Ataxia with a site in United States — 18 open to participants now, 25 under way, 4 of them phase 3. Friedreich Ataxia · United States.

Planned enrollment
Largest of 49
255 · median 32
Started
2025
with 3 others
Phase 3
10 of 71
2 open now
Primary completion
2027-11
later than 7 of 24 live
Registered
62nd of 71
by date
Lead sponsor
5 of 71
Biogen

Among the 71 studies in Friedreich Ataxia with a site in United States, this one has the largest planned enrollment of the 49 interventional ones that give a count, is one of 4 that started in 2025, is one of 10 in phase 3, reaches primary completion later than 7 of the 24 other live ones, and was the 62nd registered.

Friedreich Ataxia

111 studies on the registry are indexed under Friedreich Ataxia; 28 are open to participants now.

Browse Friedreich Ataxia studies →

Open to participants now

18 of the 71 studies in Friedreich Ataxia with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Friedreich Ataxia studies recruiting now, 9 (50%) set no upper age limit and 9 (50%) stop at 75 or younger; 15 take children under 18; 3 take healthy volunteers.

This study: 2 Years to 15 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Friedreich Ataxia with a site in United States, or all of them as a file.
02

Study summary

In this study, researchers will learn more about omaveloxolone, also known as BIIB141 or SKYCLARYS®. Omaveloxolone is already approved for people with Friedreich's Ataxia (FA) who are 16 years of age or older. However, it is not yet available for younger teens and children. The main goal of this study is to learn how omaveloxolone affects symptoms of FA and its safety in younger participants between the ages of 2 and 15 years old.

The main questions researchers want to answer in this study are:

  • How does omaveloxolone affect the participants' FA symptoms?
  • How does the body process omaveloxolone?
  • How many participants have adverse events during the study? Adverse events are health problems that may or may not be caused by the study drug.
  • Are there any changes in the participants' overall health or heart health? Researchers will use the modified Friedreich's Ataxia Rating Scale (mFARS) to test nerve function. The mFARS tests movement ability, balance, coordination, speech, and arm and leg functions. More specifically, researchers will check participants' balance, coordination, movement, and ability to perform daily tasks using the Upright Stability Score (USS). The USS is part of the mFARS questionnaire.

Researchers will also use other questionnaires to learn more about participants' symptoms, quality of life, ability to perform daily living activities, and how severe participants think their disease is.

Researchers will also note any changes as participants go through puberty. Some participants may also be invited to take part in interviews about their experiences during the study or wear devices that measure movement and physical activity during daily life.

This study will be done in 2 parts as follows:

  • Participants will be screened for up to 4 weeks to check if they can join the study.
  • In Part 1, participants will be randomly assigned to take either omaveloxolone or a placebo by mouth once a day for about 1 year. A placebo looks like the study drug but contains no real medicine.
  • Part 1 will be double blind. This means that the participants, study doctors, and study staff will not know if the participants are receiving omaveloxolone or a placebo.
  • Including screening, participants will have up to 9 clinic visits and 1 phone call during Part 1. If a participant does not join Part 2, they will have another safety follow-up phone call a month after their last dose of omaveloxolone.
  • Participants who finish Part 1 may move onto Part 2. During Part 2, participants who are at least 7 years old will be randomly assigned to receive either 150 mg or 250 mg of omaveloxolone once a day for about 104 weeks. Participants younger than 7 years old will receive 150 mg of omaveloxolone once a day for about 104 weeks.
  • During Part 2, participants will have up to 8 clinic visits and 1 phone call. Participants will also have a follow-up phone call about a month after they stop taking omaveloxolone.
  • In total, participants will have up to 17 clinic visits and 3 phone calls. Each participant will be in the study for up to 3 years.
Read the detailed description

The primary objective of Part 1 is to evaluate the efficacy of omaveloxolone as measured by upright stability score (USS) and the secondary objectives are to evaluate the efficacy of omaveloxolone as measured by additional secondary efficacy outcomes, safety of omaveloxolone and the plasma concentration of omaveloxolone after single and multiple dose administration.

The primary objective of Part 2A is to evaluate the efficacy of omaveloxolone and the secondary objectives are to characterize the efficacy of omaveloxolone as measured by additional secondary outcomes, evaluate the safety and tolerability of omaveloxolone and plasma concentration of omaveloxolone after single and multiple dose administration.

The primary objective for Part 2B is to evaluate the safety and tolerability of long-term omaveloxolone use and the secondary objective is to evaluate the efficacy of omaveloxolone following long-term use.

03

Conditions studied

  • Friedreich Ataxia

Browse trials for

04

Who can participate

Ages eligible
2 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Part 1: Key inclusion criteria:

  • Diagnosed with genetically confirmed Friedreich's Ataxia (FA), i.e., homozygous for guanine-adenine-adenine (GAA) repeat expansion in intron-1 of the frataxin gene, or GAA repeat expansion in 1 allele and with point mutations or deletions, or other non-GAA expansion mutations in the other allele.
  • Symptomatic for FA as confirmed by clinician assessment. a. Children 7 to \< 16 years must also have an upright stability score (USS) score of 10 to ≤ 34 at baseline

Part 1: Key exclusion criteria:

  • Glycosylated (HbA1c) > 11%
  • B-type natriuretic peptide (BNP) > 200 picograms per milliliter (pg/mL) at screening
  • (EF) \< 40% [based on echocardiogram (ECHO) performed at screening visit]
  • cardiac disease except mild to moderate cardiomyopathy

Part 2A: Eligibility criteria:

  • They have completed Part 1 of the study and no discontinuation criteria have been met.
  • Safety and tolerability data from Part 1 are supportive of continuation in the judgement of the investigator.

Part 2B: Eligibility criteria:

  • Participants have completed Part 1 of the study and no discontinuation criteria have been met.
  • Safety and tolerability data from Part 1 are supportive of continuation in the judgement of the Investigator.

Note: Other protocol-defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
255 participants (estimated)

Study arms

  • Experimental
    Part 1: Omaveloxolone

    Participants will receive a single oral dose of omaveloxolone once a day (QD) for up to 52 weeks in Part 1 of the study.

    Drug: Omaveloxolone

  • Placebo comparator
    Part 1: Placebo

    Participants will receive placebo, orally, QD for up to 52 weeks in Part 1 of the study.

    Drug: Placebo

  • Experimental
    Part 2A Continued Efficacy Evaluation: Omaveloxolone

    Participants will receive a single oral dose of omaveloxolone, QD for up to 104 weeks in Part 2A of the study.

    Drug: Omaveloxolone

  • Experimental
    Part 2B Safety: Omaveloxolone

    Participants will receive a single oral dose of open-label omaveloxolone, QD for up to 104 weeks in Part 2B of the study.

    Drug: Omaveloxolone

Interventions

  • Administered as specified in the treatment arm.

    Also known as: BIIB141, SKYCLARYS, RTA-408

  • DrugPlacebo

    Administered as specified in the treatment arm.

06

What researchers measure

Primary outcomes

  1. Part 1: Change From Baseline in Upright Stability Score (USS) Subscale E of Modified Friedreich's Ataxia Rating Scale (mFARS) at Week 52

    The mFARS is a validated and sensitive rating scale that was developed to quantitatively assess the severity of the neurologic features of FA in adults and adolescents. Scores on the mFARS range from 0 to 93, with lower scores indicating better neurological function. The subscales of the mFARS assessment and maximum score for each subscale are: bulbar function (Subscale A; 2 assessments of speech and cough; maximum score = 5), upper limb coordination (Subscale B; 5 assessments of coordination of movement and function in arms and hands with each limb scored individually; maximum score = 36), lower limb coordination (Subscale C; 2 assessments of coordination of movement and function of lower limbs with each limb scored individually; maximum score = 16), and upright stability (USS, Subscale E; 9 assessments of sitting posture, stance, tandem walk, and gait assessments; maximum score = 36).

    Time frame: Baseline, Week 52

  2. Part 2A: Change From Baseline in USS Subscale E of mFARS at Week 52

    The mFARS is a validated and sensitive rating scale that was developed to quantitatively assess the severity of the neurologic features of FA in adults and adolescents. Scores on the mFARS range from 0 to 93, with lower scores indicating better neurological function. The subscales of the mFARS assessment and maximum score for each subscale are: bulbar function (Subscale A; 2 assessments of speech and cough; maximum score = 5), upper limb coordination (Subscale B; 5 assessments of coordination of movement and function in arms and hands with each limb scored individually; maximum score = 36), lower limb coordination (Subscale C; 2 assessments of coordination of movement and function of lower limbs with each limb scored individually; maximum score = 16), and upright stability (USS, Subscale E; 9 assessments of sitting posture, stance, tandem walk, and gait assessments; maximum score = 36).

    Time frame: Baseline (Week 52 of Part 1), Week 52

  3. Part 2B: Number of Participants With Treatment-Emergent Adverse Event (TEAE) and Treatment-Emergent Serious Adverse Event (TESAE)

    Time frame: From the first dose of the study drug in Part 2B up to the end of follow-up period in Part 2B (up to Week 104)

  4. Part 2B: Number of Participants With Change From Baseline in Cardiac Function Assessed by Echocardiogram (ECHO) at Weeks 52 and Week 104

    Time frame: Baseline (Week 52 of Part 1), Weeks 52 and 104

  5. Part 2B: Change From Baseline in Height at Weeks 52 and Week 104

    Time frame: Baseline (Week 52 of Part 1), Weeks 52 and 104

  6. Part 2B: Change From Baseline in Weight at Weeks 52 and Week 104

    Time frame: Baseline (Week 52 of Part 1), Weeks 52 and 104

  7. Part 2B: Change From Baseline in Body Mass Index (BMI) at Weeks 52 and Week 104

    Time frame: Baseline (Week 52 of Part 1), Weeks 52 and 104

  8. Part 2B: Change From Baseline in Columbia Suicide Severity Rating Scale (C-SSRS) at Weeks 52 and Week 104

    The C-SSRS is a low-burden measure of the spectrum of suicidal ideation and behavior that was developed to assess severity and track suicidal events through any treatment of individuals ≥ 6 years of age. The C-SSRS is a clinical interview providing a summary of both ideation and behavior that can be administered by the clinician during any evaluation or risk assessment to identify the level and type of suicidality present. The assessment includes "yes" or "no" responses for 5 questions each, related to suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan) and suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, suicide). Numeric ratings are provided for severity of ideation, from 1 to 5, with 5 being the most severe.

    Time frame: Baseline (Week 52 of Part 1), Weeks 52 and 104

  9. Part 2B: Percentage of Participants at Each Tanner Stage at Weeks 52 and Week 104

    Assessment of Tanner stages (a scale of physical development) will be performed by a medical doctor experienced with this assessment. Tanner score ranges from Stage 1 (childhood) to Stage 5 (full physical maturity). Information regarding Tanner staging will be collected at baseline for all participants and will be stopped once the participant reaches Tanner Stage 5 in all gender-appropriate scales.

    Time frame: Baseline (Week 52 of Part 1), Weeks 52 and 104

  10. Part 2B: Number of Participants at Each Tanner Stage at Weeks 52 and Week 104

    Assessment of Tanner stages (a scale of physical development) will be performed by a medical doctor experienced with this assessment. Tanner score ranges from Stage 1 (childhood) to Stage 5 (full physical maturity). Information regarding Tanner staging will be collected at baseline for all participants and will be stopped once the participant reaches Tanner Stage 5 in all gender-appropriate scales.

    Time frame: Baseline (Week 52 of Part 1), Weeks 52 and 104

Secondary outcomes

  1. Part 1: Change From Baseline in Modified Friedreich's Ataxia Rating Scale (mFARS) at Week 52

    The mFARS is a validated and sensitive rating scale that was developed to quantitatively assess the severity of the neurologic features of FA in adults and adolescents. Scores on the mFARS range from 0 to 93, with lower scores indicating better neurological function. The subscales of the mFARS assessment and maximum score for each subscale are: bulbar function (Subscale A; 2 assessments of speech and cough; maximum score = 5), upper limb coordination (Subscale B; 5 assessments of coordination of movement and function in arms and hands with each limb scored individually; maximum score = 36), lower limb coordination (Subscale C; 2 assessments of coordination of movement and function of lower limbs with each limb scored individually; maximum score = 16), and upright stability (USS, Subscale E; 9 assessments of sitting posture, stance, tandem walk, and gait assessments; maximum score = 36).

    Time frame: Baseline, Week 52

  2. Part 1: Change From Baseline in Friedreich's Ataxia-Health Index (FA-HI) at Week 52

    The FA-HI is a participant reported survey that assesses overall disease burden on a 100-point scale, with 0 representing no disease burden and 100 representing the maximum level of disease burden containing 113 symptoms questions representing 18 symptomatic subscales.

    Time frame: Baseline, Week 52

  3. Part 1: Change From Baseline in Friedreich's Ataxia-Activities of Daily Living (FA-ADL)

    Participants will answer the 9 questions of the FA-ADL survey in an interview style conducted by any site staff. The FA-ADL survey assesses 9 concepts: (1) speech; (2) swallowing; (3) cutting food and handling utensils; (4) dressing; (5) personal hygiene; (6) falling; (7) walking; (8) quality of sitting position; and (9) bladder function.

    Time frame: Baseline, Week 52

  4. Part 1: Change From Baseline in Clinical Global Impressions-Severity (CGI-S) at Week 52

    The CGI-S will be conducted for all enrolled participants, 2 to \< 16 years of age. The CGI-S rating evaluates the severity of individual symptoms and treatment response in participants with mental disorders. The CGI-S is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment. A rating of 1 is considered normal, or with the least severe symptoms, a rating of 7 is extremely ill, or the worst symptoms.

    Time frame: Baseline, Week 52

  5. Part 1: Change From Baseline in Patient Global Impressions-Severity (PGI-S) at Week 52

    PGI-S will be conducted for participants 7 to \< 16 years of age. These are clinically meaningful outcome measures that are participant-relevant across all age groups and disease severities for this population. PGI -S is a 1-item questionnaire where the response is recorded on a 4-point scale scored as: 1-normal, 2-mild, 3-moderate, or 4-severe.

    Time frame: Baseline, Week 52

  6. Part 1: Number of Participants With Treatment-Emergent Adverse Event (TEAE) and Treatment-Emergent Serious Adverse Event (TESAE)

    Time frame: From first dose of study drug up to end of follow up period in Part 1 (up to Week 52)

  7. Part 1: Number of Participants With Change From Baseline in Cardiac Function Assessed by ECHO at Week 52

    Time frame: Baseline, Week 52

  8. Part 1: Change From Baseline in Height at Week 52

    Time frame: Baseline, Week 52

  9. Part 1: Change From Baseline in Weight at Week 52

    Time frame: Baseline, Week 52

  10. Part 1: Change From Baseline in Body Mass Index (BMI) at Week 52

    Time frame: Baseline, Week 52

  11. Part 1: Change From Baseline in Columbia Suicide Severity Rating Scale (C-SSRS) at Week 52

    The C-SSRS is a low-burden measure of the spectrum of suicidal ideation and behavior that was developed to assess severity and track suicidal events through any treatment of individuals ≥ 6 years of age. The C-SSRS is a clinical interview providing a summary of both ideation and behavior that can be administered by the clinician during any evaluation or risk assessment to identify the level and type of suicidality present. The assessment includes "yes" or "no" responses for 5 questions each, related to suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan) and suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, suicide). Numeric ratings are provided for severity of ideation, from 1 to 5, with 5 being the most severe.

    Time frame: Baseline, Week 52

  12. Part 1: Percentage of Participants at Each Tanner Stage at Week 52

    Assessment of Tanner stages (a scale of physical development) will be performed by a medical doctor experienced with this assessment. Tanner score ranges from Stage 1 (childhood) to Stage 5 (full physical maturity). Information regarding Tanner staging will be collected at baseline for all participants and will be stopped once the participant reaches Tanner Stage 5 in all gender-appropriate scales.

    Time frame: Baseline, Week 52

  13. Part 1: Number of Participants at Each Tanner Stage at Week 52

    Assessment of Tanner stages (a scale of physical development) will be performed by a medical doctor experienced with this assessment. Tanner score ranges from Stage 1 (childhood) to Stage 5 (full physical maturity). Information regarding Tanner staging will be collected at baseline for all participants and will be stopped once the participant reaches Tanner Stage 5 in all gender-appropriate scales.

    Time frame: Baseline, Week 52

  14. Part 1: Plasma Concentrations of Omaveloxolone

    Time frame: Pre-dose and post-dose on Day 1, Weeks 4, 12 and 26

  15. Part 2A: Change From Baseline in USS Subscale E of mFARS at Week 104

    The mFARS is a validated and sensitive rating scale that was developed to quantitatively assess the severity of the neurologic features of FA in adults and adolescents. Scores on the mFARS range from 0 to 93, with lower scores indicating better neurological function. The subscales of the mFARS assessment and maximum score for each subscale are: bulbar function (Subscale A; 2 assessments of speech and cough; maximum score = 5), upper limb coordination (Subscale B; 5 assessments of coordination of movement and function in arms and hands with each limb scored individually; maximum score = 36), lower limb coordination (Subscale C; 2 assessments of coordination of movement and function of lower limbs with each limb scored individually; maximum score = 16), and upright stability (USS, Subscale E; 9 assessments of sitting posture, stance, tandem walk, and gait assessments; maximum score = 36).

    Time frame: Baseline (Week 52 of Part 1), Week 104

  16. Part 2A: Change from baseline in mFARS at Weeks 52 and Week 104

    The mFARS is a validated and sensitive rating scale that was developed to quantitatively assess the severity of the neurologic features of FA in adults and adolescents. Scores on the mFARS range from 0 to 93, with lower scores indicating better neurological function. The subscales of the mFARS assessment and maximum score for each subscale are: bulbar function (Subscale A; 2 assessments of speech and cough; maximum score = 5), upper limb coordination (Subscale B; 5 assessments of coordination of movement and function in arms and hands with each limb scored individually; maximum score = 36), lower limb coordination (Subscale C; 2 assessments of coordination of movement and function of lower limbs with each limb scored individually; maximum score = 16), and upright stability (USS, Subscale E; 9 assessments of sitting posture, stance, tandem walk, and gait assessments; maximum score = 36).

    Time frame: Baseline (Week 52 of Part 1), Weeks 52 and 104

  17. Part 2A: Number of Participants With TEAE and TESAE

    Time frame: From the first dose of the study drug in Part 2A up to the end of follow-up period in Part 2A (up to Week 104)

  18. Part 2A: Number of Participants With Change From Baseline in Cardiac Function Assessed by ECHO at Weeks 52 and Week 104

    Time frame: Baseline (Week 52 of Part 1), Weeks 52 and 104

  19. Part 2A: Change From Baseline in Height at Weeks 52 and Week 104

    Time frame: Baseline (Week 52 of Part 1), Weeks 52 and 104

  20. Part 2A: Change From Baseline in Weight at Weeks 52 and Week 104

    Time frame: Baseline (Week 52 of Part 1), Weeks 52 and 104

  21. Part 2A: Change From Baseline in BMI at Weeks 52 and Week 104

    Time frame: Baseline (Week 52 of Part 1), Weeks 52 and 104

  22. Part 2A: Change From Baseline in C-SSRS at Weeks 52 and Week 104

    The C-SSRS is a low-burden measure of the spectrum of suicidal ideation and behavior that was developed to assess severity and track suicidal events through any treatment of individuals ≥ 6 years of age. The C-SSRS is a clinical interview providing a summary of both ideation and behavior that can be administered by the clinician during any evaluation or risk assessment to identify the level and type of suicidality present. The assessment includes "yes" or "no" responses for 5 questions each, related to suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan) and suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, suicide). Numeric ratings are provided for severity of ideation, from 1 to 5, with 5 being the most severe.

    Time frame: Baseline (Week 52 of Part 1), Weeks 52 and 104

  23. Part 2A: Percentage of Participants at Each Tanner Stage at Weeks 52 and Week 104

    Assessment of Tanner stages (a scale of physical development) will be performed by a medical doctor experienced with this assessment. Tanner score ranges from Stage 1 (childhood) to Stage 5 (full physical maturity). Information regarding Tanner staging will be collected at baseline for all participants and will be stopped once the participant reaches Tanner Stage 5 in all gender-appropriate scales.

    Time frame: Baseline (Week 52 of Part 1), Weeks 52 and 104

  24. Part 2A: Number of Participants at Each Tanner Stage at Weeks 52 and Week 104

    Assessment of Tanner stages (a scale of physical development) will be performed by a medical doctor experienced with this assessment. Tanner score ranges from Stage 1 (childhood) to Stage 5 (full physical maturity). Information regarding Tanner staging will be collected at baseline for all participants and will be stopped once the participant reaches Tanner Stage 5 in all gender-appropriate scales.

    Time frame: Baseline (Week 52 of Part 1), Weeks 52 and 104

  25. Part 2A: Plasma Concentrations of Omaveloxolone

    Time frame: Pre-dose and post-dose on Day 1, Weeks 4, 12 and 26

  26. Part 2B: Change From Baseline in mFARS Including USS at Weeks 52 and Week 104

    The mFARS is a validated and sensitive rating scale that was developed to quantitatively assess the severity of the neurologic features of FA in adults and adolescents. Scores on the mFARS range from 0 to 93, with lower scores indicating better neurological function. The subscales of the mFARS assessment and maximum score for each subscale are: bulbar function (Subscale A; 2 assessments of speech and cough; maximum score = 5), upper limb coordination (Subscale B; 5 assessments of coordination of movement and function in arms and hands with each limb scored individually; maximum score = 36), lower limb coordination (Subscale C; 2 assessments of coordination of movement and function of lower limbs with each limb scored individually; maximum score = 16), and upright stability (USS, Subscale E; 9 assessments of sitting posture, stance, tandem walk, and gait assessments; maximum score = 36).

    Time frame: Baseline (Week 52 of Part 1), Weeks 52 and 104

  27. Parts 2A and 2B: Change From Baseline in FA-HI at Weeks 52 and Week 104

    The FA-HI is a participant reported survey that assesses overall disease burden on a 100-point scale, with 0 representing no disease burden and 100 representing the maximum level of disease burden containing 113 symptoms questions representing 18 symptomatic subscales.

    Time frame: Baseline (Week 52 of Part 1), Weeks 52 and 104

  28. Parts 2A and 2B: Change From Baseline in PGI-S at Weeks 52 and Week 104

    PGI-S will be conducted for participants 7 to \< 16 years of age. These are clinically meaningful outcome measures that are participant-relevant across all age groups and disease severities for this population. PGI -S is a 1-item questionnaire where the response is recorded on a 4-point scale scored as: 1-normal, 2-mild, 3-moderate, or 4-severe.

    Time frame: Baseline (Week 52 of Part 1), Weeks 52 and 104

  29. Parts 2A and 2B: Change From Baseline in CGI-S at Weeks 52 and Week 104

    The CGI-S will be conducted for all enrolled participants, 2 to \< 16 years of age. The CGI-S rating evaluates the severity of individual symptoms and treatment response in participants with mental disorders. The CGI-S is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment. A rating of 1 is considered normal, or with the least severe symptoms, a rating of 7 is extremely ill, or the worst symptoms.

    Time frame: Baseline (Week 52 of Part 1), Weeks 52 and 104

  30. Parts 2A and 2B: Change from baseline in FA-ADL at Part 2A Weeks 52 and Week 104

    Participants will answer the 9 questions of the FA-ADL survey in an interview style conducted by any site staff. The FA-ADL survey assesses 9 concepts: (1) speech; (2) swallowing; (3) cutting food and handling utensils; (4) dressing; (5) personal hygiene; (6) falling; (7) walking; (8) quality of sitting position; and (9) bladder function.

    Time frame: Baseline (Week 52 of Part 1), Weeks 52 and 104

07

Study locations

34 sites
08

References and documents

Related links

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Nov 2027, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2025
First posted
May 1, 2025
StartActual
Jun 9, 2025
Primary completionEst.
Nov 16, 2027
CompletionEst.
Nov 22, 2029
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Recruiting→Active, not recruiting
    + 5 other changes: identifiers, verification date, description, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06953583
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
May 1, 2025
Start date
Jun 9, 2025
Primary completion
Nov 16, 2027 (estimated)
Completion
Nov 22, 2029 (estimated)
Last update
Oct 2, 2026

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omaveloxolone

Start the discussion